Laboratory tests have shown that the three-shot course of Pfizer-BioNTech vaccine can neutralize Omicron, while the two-shot seems to be less effective.
Pfizer said its booster dose of COVID-19 vaccine can neutralize new Omicron variants In laboratory studies, even the first two doses seem to be significantly less effective.
Wednesday’s statement is the first official statement from a vaccine manufacturer on the current efficacy of Omicron injections.
Pfizer and its partner BioNTech stated that laboratory tests showed that the booster dose increased the level of so-called neutralizing antibodies against Omicron by 25 times. Their results have not been peer reviewed.
According to early laboratory studies using vaccinated serum, the level of anti-Omicron antibodies produced in the third booster vaccination was about the same as that seen after the second vaccination with other variants.
Scientists speculate that the surge in antibodies from the third dose of the COVID-19 vaccine may be enough to offset any decline in effectiveness.
Antibody levels can predict the effectiveness of vaccines in preventing coronavirus infections, but they are only a layer of the immune system’s defenses. Pfizer said the two doses of the vaccine may still induce protection against serious diseases.
Pfizer CEO Albert Bourla said in a statement: “Although two doses of the vaccine may still protect against serious diseases caused by the Omicron strain, it is clear from these preliminary data that The third dose of vaccine can maximize protection.”
Bourla said: “Ensure that as many people as possible get the first two doses of the vaccine. Intensified vaccination is still the best course of action to prevent the spread of COVID-19.”
The two companies also stated that a specific version of the Omicron coronavirus vaccine currently under development will be available in March.
The results of the study are roughly in line with a preliminary study published on Tuesday by researchers from the African Health Research Institute in South Africa, which stated that Omicron can partially evade the protection of two doses of Pfizer-BioNTech vaccine. The results of the study also indicate that the third shot may help fight infection.
The discovery of the first Omicron case two weeks ago coincided with a surge in the number of infections worldwide.
This variant raises concerns about a global COVID-19 comeback.
According to the World Health Organization, to date, Omicron has been found in 57 countries/regions, many of which Re-impose travel restrictions To prevent spread.
There are no deaths related to this variant, and some health officials say that although Omicron may be more contagious than previous variants, Early signs It may cause less serious diseases.